The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: anti-inflammatory anaesthetics. Buy the report here.
Smarter leaders trust GlobalData
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
80+ innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 730,000 patents, there are 80+ innovation areas that will shape the future of the industry.
Within the emerging innovation stage, engineered multispecific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Peptide pharmacophores, antibody-drug conjugates, and neuroprotective drugs are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are amyloid precursor targeted therapies and modified vector HIV-1 vaccines, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Anti-inflammatory anaesthetics is a key innovation area in pharmaceutical industry
Local anaesthetics have potent anti-inflammatory properties with fewer side effects compared with traditional anti-inflammatory agents of the NSAID and steroid groups.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 335+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-inflammatory anaesthetics.
Key players in anti-inflammatory anaesthetics – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to anti-inflammatory anaesthetics
Source: GlobalData Patent Analytics
Grunenthal is the leading patent filer for anti-inflammatory anaesthetics. The company develops drugs for the management of pain. Its portfolio includes a wide range of medicinal products for chronic and acute pain, nociceptive and neuropathic pain. Its major products include Tramal used for the treatment of moderate to severe pain; Transtec used to treat moderate to severe cancer pain; and Vimovo used for the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. Headquartered in Aachen, Germany, the company distributes products and operates in Europe, Latin America and the US.
In terms of application diversity, Nippon Zoki Pharmaceutical is the top company, followed by Shionogi and Glenmark Pharmaceuticals.
By means of geographic reach, Xenon Pharmaceuticals holds the top position. While HRD and Sorrento Therapeutics are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
